Abstract: The present invention generally relates to the field of dietary therapies for treating disorders associated with mitochondrial dysfunction, including epilepsy.

Abstract: Disclosed are oral care compositions of novel phosphono-phosphate and anionic group containing polymer compositions that have targeted uses with divalent cations and surfaces having divalent cations. These compounds can be used to deliver anionic character to surfaces such as calcium hydroxyapatite for use in oral care applications.

Abstract: The present invention relates to a compound represented by formula (I), a tautomer thereof or a pharmaceutically acceptable salt thereof, and relates to applications thereof in the preparation of drugs for treating FXR related diseases.

Abstract: A well treatment fluid composition that includes a tetrakis(hydroxyorgano)phosphonium salt and at least one oxidizing viscosity breaker. Methods for preparing a microbial viscosity breaker composition and treating a subterranean formation are also presented.

Abstract: Biofouling may be prevented or at least mitigated by employing a cinnamaldehyde additive to augment the affect of the conventional biocide. Exemplary cinnamaldehyde additives include, but are not limited to, cinnamaldehyde, cinnamic acid and cinnamyl alcohol. A cinnamaldehyde additive by itself, in some embodiments, may also inhibit biofouling.

Abstract: Provided herein are compositions for the treatment and/or prevention of cardiovascular disease (CVD), and methods of application and use thereof. In particular, the present invention provides treatment and/or prevention of cardiovascular disease with compounds that inhibit the production of TMA in the gut, such as 3,3-dimethyl-1-butanol (DMB) or other compounds represented by Formula I or as shown in FIGS. 20-23.

Abstract: Pharmaceutical compositions of the invention comprise sulfamoylbenzamide derivative useful as pregenomic RNA encapsidation inhibitors, useful for the treatment of Hepatitis B virus (HBV) infection.

Abstract: A synergistic antimicrobial composition having two components. The first component is a hydroxymethyl-substituted phosphorus compound. The second component is one of the following biocides: hexahydro-1,3,5-tris(2-hydroxyethyl)-s-triazine, 2,6-dimethyl-1,3-dioxan-4-yl acetate or ortho-phenylphenol or its alkali metal or ammonium salts.

Abstract: The invention relates to a cosmetic composition comprising, in a physiologically acceptable aqueous medium, a cucurbic acid compound of formula (I) in which R1 represents a radical COOR3, where R3 denotes H or a C1-C4 alkyl radical, which is optionally substituted by one or more hydroxyl groups; R2 represents a hydrocarbon radical having from 1 to 18 carbon atoms; and a copolymer of 2-acrylamido-2-methylpropanesulphonic acid and hydroxylated C2-C4 alkyl(meth)acrylate. Application to the care and make-up of keratin materials.

Abstract: The invention relates to a method for cosmetically treating oily skin, including the topical application onto the skin of a composition containing a jasmonic acid compound in a physiologically acceptable medium.

Abstract: A salt compound, and methods for mitigating neurodegeneration, effecting neuroprotection and/or effecting cognition enhancement in a subject using the salt compound are described. Neurological or cognitive conditions are treated by administering to a subject an effective amount of a therapeutic salt compound comprising a nitrate ester.

Abstract: A synergistic composition comprising a THP salt and a biopenetrant, in which the biopenetrant comprises a polymer of an unsaturated carboxylic acid or a copolymer of an unsaturated carboxylic acid with a sulphonic acid, said polymer or copolymer being terminated by a mono- or diphosphonated unsaturated carboxylic acid group or having such monomers incorporated into the polymer backbone. This composition acts synergistically to enhance the biocidal efficacy of the THP salt against both planktonic (free-swimming) and sessile (attached) bacteria, and also acts synergistically to enhance the efficacy of the THP salt in the dissolution of iron sulphide scale.

Abstract: The invention generally relates to compositions and methods of their use. More specifically, the invention relates to the use of a compound in modulating erythropoiesis in a subject by mediating the activity and/or quantity of a member present in the LPA3-mediated signaling pathway, such as lysophosphatidic acid receptor subtype 3 (LPA3).

Abstract: The invention provides a method of ameliorating a blood-brain barrier disorder, as well as a method of treating a disease accompanied by a blood-brain barrier disorder and a method of treating a cerebral ischemic disease, by administering a prothymosin ?, or a protein or polypeptide possessing the same function as the prothymosin ?. The invention also provides polypeptides useful in the context of the aforesaid methods.

Abstract: A combination biocide (Glutaraldehyde or OPA), quaternary phosphonium biocide (preferably TTPC), alcohol (preferably isopropyl alcohol), and functional excipients for the oil and gas recovery industry. The functional excipients for the oil and gas recovery industry are a cellulose type proppant, a poloxamer wetting agent, a friction-reducing pluronic block copolymer, a drag reducing agent such as polyethylene oxide, and a flocculating agent. The OPA may be of the dialdehyde C6H4(CHO)2 form, and the Glutaraldehyde of formula C5H8O2. Both will produce an inherent bacteriostatic effect and lower surface tension and thus aids in the spread of the TTPC on the biofilm covered surface where it is readily absorbed by the negative surfaces of proteins and bacteria. It thus serves as a binding agent between the TTPC and the application surface. The foregoing constituents are combined in preferred concentrations within acceptable ranges to provide a synergistic biological chemical complementarity system.

Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein A is a 6-membered aromatic ring containing carbon atoms and 0-3 nitrogen atoms as ring members, said ring optionally substituted with 1-5 substituents independently selected from R2; R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R21; R21 is independently H, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, CN or NO2; and Q is as defined in the disclosure.

Abstract: Embodiments of the invention involve treating skin afflictions by the topical or oral use of organophosphates. By effectively reducing or eliminating the population of Demodex mites in affected skin areas and areas where Demodex mites may exist, this treatment achieves a more complete remission of clinical signs and symptoms of the skin afflictions than any previously described method. Embodiments of the invention are useful for treating skin afflictions including common acne, seborrheic dermatitis, perioral dermatitis, an acneform rash, transient acantholytic dermatosis, acne necrotica milliaris, psoriasis, steroid induced dermatitis, primary irritation dermatitis, rosacea and for diagnositic methods thereof.

Abstract: Biofouling may be prevented or at least mitigated by employing a cinnamaldehyde additive to augment the affect of the conventional biocide. Exemplary cinnamaldehyde additives include, but are not limited to, cinnamaldehyde, cinnamic acid and cinnamyl alcohol. A cinnamaldehyde additive by itself, in some embodiments, may also inhibit biofouling.

Abstract: Disclosed are biocide compositions. The compositions are useful in applications relating to the production, transportation, storage, and separation of crude oil and natural gas. Also disclosed are methods of using the compositions, particularly in applications relating to the production, transportation, storage, and separation of crude oil and natural gas.

Abstract: Glycerophosphate salts have been found to hasten the healing of wounds and minimize the formation of scars, particularly when it is first applied to a wound about 0 to about 7 days after the wound is inflicted. Methods and compositions are provided for treating wounds using a composition comprising an effective amount of glycerophosphate salt. In particular, methods are provided for treating wounds using calcium glycerophosphate (CGP), for accelerating the healing process, reducing pain and scar formation, and for the cosmetic reducing, excision, erasure and/or complete repair of scars (scar revision).

Abstract: The present invention relates to a dental implant having an enhanced early stability and a method for manufacturing same, and more specifically to a dental implant and a method for manufacturing same which assure early stability and fixation power of an implant by suppressing early osteolysis after an implant procedure, and allowing better bone coherence of the implant surface during an osteogenic period by controlling the speed of bone remodeling.

Abstract: As disclosed herein, co-administration of pimavanserin with an agent that ameliorates one or more cholinergic abnormalities can have a synergistic effect on the efficacy of the agent. Disclosed herein are compositions which include pimavanserin in combination with an agent that ameliorates one or more cholinergic abnormalities. Also disclosed herein are methods for ameliorating or treating a disease condition characterized by one or more cholinergic abnormalities that can include administering pimavanserin in combination with an agent that ameliorates one or more cholinergic abnormalities.

Abstract: The present disclosure relates to a cosmetic or dietary composition for combating human or animal hair loss and/or promoting hair growth and/or regrowth and/or enhancing the beauty thereof (shine, softness, strength) and/or enhancing scalp comfort, comprising at least miliacin in a proportion greater than 0.1% by mass with respect to the total mass of the composition and polar lipids in a proportion greater than 0.1% by mass with respect to the total mass of the composition, including sphingolipids, particularly ceramides and/or glycosylceramides, and/or phospholipids in a proportion greater than 0.1% by mass with respect to the total mass of the composition. The present disclosure further relates to the use of such a composition, and the method for preparing such a composition.

Abstract: A composition for treating an inorganic slurry, the composition comprising: (a) a tetrakis (hydroxyorgano) phosphonium salt; and (b) a dispersant selected from the group consisting of (i) a phosphonated compound containing at least one tertiary nitrogen atom, (ii) a phosphonated oligomer of an unsaturated acid, (iii) a homopolymer of an unsaturated acid, and (iv) a polyphosphate.

Abstract: Provided are biocidal compositions comprising: a hydroxymethyl-substituted phosphorus compound and an isothiazolinone compound selected from 1,2-benzisothiazolin-3-one, 2-methyl-1,2-benzisothiazolin-3-one, and mixtures thereof. The compositions are useful for controlling microorganisms in aqueous or water-containing systems.

Abstract: Glycerophosphate salts have been found to drastically improve a laparoscopic surgery by reducing the inflammatory response inflicted by the surgery and enhancing wound healing. Methods and devices for improving the laparoscopic surgery using a composition comprising an effective amount of a glycerophosphate salt are described.

Abstract: Provided are biocidal compositions comprising: a hydroxymethyl-substituted phosphorus compound and a polymeric biguanide. The compositions are useful for controlling microorganisms in aqueous or water-containing systems.

Abstract: Cu(I) complexes of the type [Cu(thp)4]n[X]?n, wherein thp is a tris(hydroxymethyl)phosphine, X is a counteranion, n=1-4, for the use as antineoplistic agents against solid tumors in humans.

Abstract: The present invention relates to a prodrug, comprising a pharmaceutically and/or diagnostically active compound, and one or more bisphosphonate groups, to a process for producing such a prodrug, and to a pharmaceutical composition comprising said prodrug, to be used for the treatment of bone-related disorders such as bone cancer.

Abstract: The present invention relates to the use of osmolytes for treating allergic or viral respiratory diseases, e.g. allergic rhinitis (hay fever) as well as rhinovirus and/or adenovirus infections. The invention also relates to a medicament preparation containing one or more compounds from the group of osmolytes. The group of osmolytes used in the invention comprises various low-molecular substances, more specifically ectoine, 4,5,6,7-tetrahydro-2-methyl-1H-[1,3]-diazepine-4-S-carboxylic acid (homoectoine), hydroxyectoine, di-myo-inositol-phosphate (DIP), to cyclic 2,3-diphosphoglycerate (cDPG), 1,1-diglycerol phosphate (DGP), ?-mannosylglycerate (firoin), ?-mannosylglyceramide (firoin-A), dimannosyl-diinositol phosphate (DMIP), glucosylglycerol, taurine, betaine, citrulline, and/or a derivative, e.g. an acid, salt, or ester of said compounds.

Abstract: Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, wherein A is a 6-membered aromatic ring containing carbon atoms and 0-3 nitrogen atoms as ring members, said ring optionally substituted with 1-5 substituents independently selected from R2; R1 is C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C4-C7 alkylcycloalkyl or C4-C7 cycloalkylalkyl, each optionally substituted with one or more substituents independently selected from R21; R21 is independently H, halogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C1-C6 alkylthio, C1-C6 haloalkylthio, C1-C6 alkylsulfinyl, C1-C6 haloalkylsulfinyl, C1-C6 alkylsulfonyl, C1-C6 haloalkylsulfonyl, CN or NO2; and Q is as defined in the disclosure.

Abstract: At least one phytosphingosine salicylate derivative and at least one lysate of at least one microorganism of the genus Bifidobacterium. Composition, combination. Use, including cosmetic use for reinforcing the repair and regeneration capacity of an epithelium, especially an epidermis, in particular an aged epidermis.

Abstract: A method for treating hair loss in mammals uses compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth. Compositions containing 2-decarboxy-2-phosphinico prostaglandin derivatives can also be used to lower intraocular pressure and treat bone disorders.

Abstract: The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements and/or similar preservative standards (e.g., EP and JP).

Abstract: A method for reducing the effects of biological contamination in a hydrocarbon-containing system comprising the steps of continuously adding a formulation comprising tris(hydroxymethyl)phosphine or a tetrakis(hydroxymethyl)phosphonium salt to the system for one day or more; monitoring the efficacy of the continuous treatment by an assessment of the extent to which there is any effect on the environment that is attributable to metabolic activity of active microbes present in the system; wherein the tris(hydroxymethyl)phosphine or tetrakis(hydroxymethyl)phosphonium salt is added at a concentration of from 1 to 30 ppm based on the total volume of aqueous fluid added to the system, and wherein the formulation is added to the system at a stage to minimize incompatibility with any other chemicals that are added to the aqueous fluid.

Abstract: A synergistic antimicrobial composition comprising: (a) a hydroxymethyl-substituted phosphorus compound selected from the group consisting of tetrakis(hydroxymethyl)phosphonium salts and tris(hydroxymethyl)phosphine; and (b) tris(hydroxymethyl)nitromethane.

Abstract: A synergistic antimicrobial composition having two components. The first component is a hydroxymethyl-substituted phosphorus compound. The second component is cis-1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride.

Abstract: A synergistic antimicrobial composition comprising: (a) a hydroxymethyl-substituted phosphorus compound selected from the group consisting of tetrakis(hydroxymethyl)phoshponium salts and tris(hydroxymethyl)phosphine; and (b) tris(hydroxymethyl)nitromethane.

Abstract: An anti-stick agent that may be incorporated into an aqueous medium to assist in the prevention of soils and bodily exudates adhering to the skin. A substrate may be utilized to assist in delivering the anti-stick agent to the skin.

Abstract: Provided are a drug, a cosmetic, etc. for promoting production of ceramide. Provided is a ceramide production promoter including a compound represented by the formula (1) or salts thereof as an active ingredient (in the formula, R1 represents a phosphono group or a hydrogen atom, R2 represents an alkyl group having 8 to 24 carbon atoms or an acyl group having 8 to 24 carbon atoms, and R3 represents an alkyl group having 1 to 24 carbon atoms when R1 represents a phosphono group or represents a phosphono group when R1 represents a hydrogen atom, or a salt thereof as an active ingredient.

Abstract: The present application discloses nanoparticles, particularly nanoparticles of superparamagnetic iron oxide, which find utility in iron therapy and diagnostic imaging such as magnetic resonance (MR). The disclosed nanoparticles have been treated with an ?-hydroxyphosphonic acid conjugate containing polyethylene glycol as a hydrophilic moiety to render the nanoparticles sufficiently hydrophilic to find utility in diagnostic imaging. Among the modified hydrophilic nanoparticles disclosed are those in which the hydrophilic moieties of the modifying conjugate are polyethylene oxide-based polymers and have a molecular weight greater than 5,000 dalton and less than or equal to about 30,000 daltons. Surprisingly, these nanoparticles have a more rapid and complete processing in liver of retained nanoparticles when compared to similar nanoparticles in which the PEG-based hydrophilic moiety has a molecular weight less than 5,000.

Abstract: A method for treating an inorganic slurry to preserve the slurry against bacterial contamination, including (I) providing a slurry in a substantially homogeneous phase, and then (II) adding to the slurry an effective amount of a composition containing: (a) a tetrakis (hydroxyorgano) phosphonium salt selected from the group consisting of tetrakis (hydroxymethyl) phosphonium sulphate, tetrakis (hydroxymethyl) phosphonium chloride, tetrakis (hydroxymethyl) phosphonium phosphate, tetrakis (hydroxymethyl) phosphonium nitrate and tetrakis (hydroxymethyl) phosphonium oxalate; and (b) a dispersant selected from the group consisting of (i) a phosphonated compound containing at least one tertiary nitrogen atom and (ii) a homopolymer of an unsaturated acid; and (III) preserving the slurry against bacterial contamination, whilst avoiding instantaneous heterogeneous thickening of the slurry due to the tetrakis (hydroxyorgano) phosphonium salt.

Abstract: A composition and method of treating Alzheimer's disease or a dementia of vascular origin are disclosed. The composition and method utilize an endothelin antagonist as the active agent to treat Alzheimer's disease or a dementia of vascular origin in mammals, including humans.

Abstract: The invention relates to pharmacology and medicine, in particular to a class of mitochondrially-addressed compounds which can be used in the pharmaceutical compositions of medicinal agents (preparations) for preventing and treating cardiovascular diseases and diseases and pathological conditions caused by disturbed blood circulation or oxygen supply to tissues and organs.

Abstract: The present invention relates to compounds as novel thymidylate synthase inhibitors, novel strategies to treat or prevent neoplasia in a subject, methods and compositions thereof.

Abstract: The present invention discloses pharmaceutical/nutritional compositions and methods for alleviating symptoms associated with premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). The pharmaceutical/nutritional compositions include at least 2% (w/w) phosphatidyl-L-serine, or salts thereof, out of a total effective composition, as a first effective ingredient; and a suitable amount of at least one bio-available form of magnesium as a second effective ingredient. Preferably, the bio-available form of magnesium is magnesium oxide, magnesium citrate, magnesium hydroxide, magnesium stearate, or a magnesium salt of the phosphatidyl-L-serine. Preferably, the composition further includes a pharmaceutical or nutritional excipient. Preferably, the total effective composition is administrable in a multi-part regimen. Preferably, the total effective composition is administrable by intravenous or oral delivery.

Abstract: The invention features compositions, methods, and kits for the administration of an oxidatively transformed carotenoid, or a fractionated component thereof, for use in aquaculture.

Abstract: A synergistic composition comprising a THP salt and a biopenetrant, in which the biopenetrant comprises a polymer of an unsaturated carboxylic acid or a copolymer of an unsaturated carboxylic acid with a sulphonic acid, said polymer or copolymer being terminated by a mono- or diphosphonated unsaturated carboxylic acid group or having such monomers incorporated into the polymer backbone. This composition acts synergistically to enhance the biocidal efficacy of the THP salt against both planktonic (free-swimming) and sessile (attached) bacteria, and also acts synergistically to enhance the efficacy of the THP salt in the dissolution of iron sulphide scale.

Abstract: Provided are a drug, a cosmetic, etc. for promoting production of ceramide. Provided is a ceramide production promoter including a compound represented by the formula (1) or salts thereof as an active ingredient (in the formula, R1 represents a phosphono group or a hydrogen atom, R2 represents an alkyl group having 8 to 24 carbon atoms or an acyl group having 8 to 24 carbon atoms, and R3 represents an alkyl group having 1 to 24 carbon atoms when R1 represents a phosphono group or represents a phosphono group when R1 represents a hydrogen atom, or a salt thereof as an active ingredient.

Abstract: The present invention relates to a method of preventing or alleviating the problems associated with corrosion and to novel formulations for use in such a method.